September 9, 2025 2:58 AM PDT
Europe Medical Cannabis Market Forecast by 2033
Market Size in 2024: USD 2,586.1 Million
Market Forecast in 2033: USD 12,652.9 Million
Market Growth Rate 2025-2033: 18.33%
The Europe medical cannabis market is projected to surge from USD 2,586.1 million in 2024 to USD 12,652.9 million by 2033, registering a CAGR of 18.33%. Germany dominates with the largest share, while the UK emerges as the fastest-growing country, driven by liberalising regulations, soaring patient demand and rapid import growth.
Growth Drivers Powering the European Medical Cannabis Market
Germany’s Dominant Demand and Record Import Volumes
Compared to the previous year, in 2024, Germany's import of cannabis flower increased by 70% and was worth 34.6 tonnes. This data indicates the total number of patients in the country, which has gone beyond 200,000. Germany represents 45% of the total European medical sales and distributes THC-rich prescriptions via the statutory insurance system, thus producing a visible, price-supported pull-through, which is the basis of regional demand.
Regulatory Liberalisation Across Member States
Through 2020, the Court of Justice of the EU has set a definition for CBD, which states that it is not a narcotic; as a result, six more countries decided to legalise medical cannabis. France initiated a reimbursable pilot for chronic pain, while Italy and Poland increased quotas for cultivation. This way, each new national programme enlarges the patient pool that can be treated and legitimises cross-border supply chains.
Clinical Validation and Product Standardisation
The likes of Sativex and Epidiolex are among the standardised medicines included in national formularies, while 17 clinical trials in the EU have been ongoing to explore the use of cannabis in the treatment of epilepsy, MS, and cancer pain. The Good Manufacturing Practice (GMP) certified facilities in the Netherlands and Denmark provide 3,370 kg per year for the market, they also ensure the consistency of THC: CBD ratios in each batc,h meeting prescriber requirements and thus, facilitating uptake.
Request a Free Sample Copy of the Report: https://www.imarcgroup.com/Europe-Medical-Cannabis-Market/requestsample
Europe Medical Cannabis Market Segmentation
Analysis by Species
Analysis by Derivative
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
Analysis by Application
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
Analysis by End Use
- Pharmaceutical Industry
- Research and Development Centers
- Others
Analysis by Route of Administration
- Oral Solutions and Capsules
- Smoking
- Vaporizers
- Topicals
- Others
Analysis by Country
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Europe Medical Cannabis Market News
- March 2025: Canopy Growth introduced four new Tweed strains cultivated in Portugal, expanding German pharmacy shelves under EU-GMP certification.
- February 2025: Germany’s Q3 2024 imports hit 22.7 tonnes, a 70% quarterly increase, underscoring surging patient demand.
- January 2025: France expanded its reimbursable medical-cannabis pilot to 3,000 chronic-pain patients, moving toward nationwide adoption.
- December 2024: The Netherlands exported 3,370 kg of GMP-certified flower to EU neighbours, reinforcing its role as Europe’s cultivation hub.
Key highlights of the Report:
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Europe Medical Cannabis Market Forecast by 2033
Market Size in 2024: USD 2,586.1 Million
Market Forecast in 2033: USD 12,652.9 Million
Market Growth Rate 2025-2033: 18.33%
The Europe medical cannabis market is projected to surge from USD 2,586.1 million in 2024 to USD 12,652.9 million by 2033, registering a CAGR of 18.33%. Germany dominates with the largest share, while the UK emerges as the fastest-growing country, driven by liberalising regulations, soaring patient demand and rapid import growth.
Growth Drivers Powering the European Medical Cannabis Market
Germany’s Dominant Demand and Record Import Volumes
Compared to the previous year, in 2024, Germany's import of cannabis flower increased by 70% and was worth 34.6 tonnes. This data indicates the total number of patients in the country, which has gone beyond 200,000. Germany represents 45% of the total European medical sales and distributes THC-rich prescriptions via the statutory insurance system, thus producing a visible, price-supported pull-through, which is the basis of regional demand.
Regulatory Liberalisation Across Member States
Through 2020, the Court of Justice of the EU has set a definition for CBD, which states that it is not a narcotic; as a result, six more countries decided to legalise medical cannabis. France initiated a reimbursable pilot for chronic pain, while Italy and Poland increased quotas for cultivation. This way, each new national programme enlarges the patient pool that can be treated and legitimises cross-border supply chains.
Clinical Validation and Product Standardisation
The likes of Sativex and Epidiolex are among the standardised medicines included in national formularies, while 17 clinical trials in the EU have been ongoing to explore the use of cannabis in the treatment of epilepsy, MS, and cancer pain. The Good Manufacturing Practice (GMP) certified facilities in the Netherlands and Denmark provide 3,370 kg per year for the market, they also ensure the consistency of THC: CBD ratios in each batc,h meeting prescriber requirements and thus, facilitating uptake.
Request a Free Sample Copy of the Report: https://www.imarcgroup.com/Europe-Medical-Cannabis-Market/requestsample
Europe Medical Cannabis Market Segmentation
Analysis by Species
Analysis by Derivative
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
Analysis by Application
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
Analysis by End Use
- Pharmaceutical Industry
- Research and Development Centers
- Others
Analysis by Route of Administration
- Oral Solutions and Capsules
- Smoking
- Vaporizers
- Topicals
- Others
Analysis by Country
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Europe Medical Cannabis Market News
- March 2025: Canopy Growth introduced four new Tweed strains cultivated in Portugal, expanding German pharmacy shelves under EU-GMP certification.
- February 2025: Germany’s Q3 2024 imports hit 22.7 tonnes, a 70% quarterly increase, underscoring surging patient demand.
- January 2025: France expanded its reimbursable medical-cannabis pilot to 3,000 chronic-pain patients, moving toward nationwide adoption.
- December 2024: The Netherlands exported 3,370 kg of GMP-certified flower to EU neighbours, reinforcing its role as Europe’s cultivation hub.
Key highlights of the Report:
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.